CHO-K1 Human GPR35 Stable Cell

CHO-K1/Human GPR35 Stable Cell

Item	Cat#	Price
Stable Cell Line	SNB-G-0241A	$19,800
Compound Testing Services	CT-001	$1,850 per 384w plate *(Up To 16 cpds Dose)*

Ask For A Custom Quote

Product Description

GPR35 is an orphan G protein-coupled receptor primarily coupled to Gi/o proteins. It is highly expressed in immune cells (e.g., macrophages, neutrophils) and the gastrointestinal tract, with additional presence in the nervous system and some endocrine organs. This receptor can be activated by various ligands, including the endogenous metabolites kynurenic acid and lysophosphatidic acid. Its core functions involve modulating immune responses, inflammatory processes, and metabolic homeostasis, playing roles in suppressing pro-inflammatory cytokine release, regulating insulin secretion, and pain perception. Consequently, GPR35 is regarded as a potential therapeutic target for inflammatory bowel disease, type 2 diabetes, and neuropathic pain.

Screeningbio’s CHO-K1/Human GPR35 cell line overexpress GPR35 receptor and is designed to detect inhibition in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.

Product Specifications

Target Type	GPCR
Species	Human
HGNC Symbol	GPR35
Accession Number	NM_005301 (Hs)
Parental Line	CHO-K1
Lot#	See Vial
Storage	Liquid Nitrogen

Data

CHO-K1/Human GPR35 Agonist Assay. CHO-K1/Human GPR35 cells were stimulated with 2.5 μM Forskolin and treated with reference agonist. The assay was run based on Revvity cAMP HTRF protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software. — **CHO-K1/Human GPR35 Agonist Assay.** CHO-K1/Human GPR35 cells were stimulated with 2.5 μM Forskolin and treated with reference agonist. The assay was run based on Revvity cAMP HTRF protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software.

Target Background

GPR35 is an orphan G protein-coupled receptor primarily coupled to Gi/o proteins. It is highly expressed in immune cells (e.g., macrophages, neutrophils) and the gastrointestinal tract, with additional presence in the nervous system and some endocrine organs.

This receptor can be activated by various ligands, including the endogenous metabolites kynurenic acid and lysophosphatidic acid. Its core functions involve modulating immune responses, inflammatory processes, and metabolic homeostasis, playing roles in suppressing pro-inflammatory cytokine release, regulating insulin secretion, and pain perception.

Consequently, GPR35 is regarded as a potential therapeutic target for inflammatory bowel disease, type 2 diabetes, and neuropathic pain.